EXACT Sciences Corporation  

(Public, NASDAQ:EXAS)   Watch this stock  
Find more results for EXAS
24.82
+0.11 (0.45%)
Nov 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 24.71 - 25.42
52 week 10.69 - 26.79
Open 25.01
Vol / Avg. 540,671.00/1.64M
Mkt cap 2.08B
P/E     -
Div/yield     -
EPS -1.02
Shares 84.25M
Beta 1.36
Inst. own 89%
Feb 18, 2015
Q4 2014 Exact Sciences Corp Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 20, 2014
Exact Sciences Corp at Canaccord Genuity Medical Technologies & Diagnostics Forum
Nov 20, 2014
Exact Sciences Corp at Goldman Sachs US Emerging / SMID Cap Growth Conference
Nov 12, 2014
Exact Sciences Corp at Stephens Fall Investment Conference
Oct 27, 2014
Q3 2014 Exact Sciences Corp Earnings Call
Oct 27, 2014
Q3 2014 Exact Sciences Corp Earnings Release
Sep 4, 2014
Exact Sciences Corp at Robert W. Baird & Co. Inc Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -1122.44%
Operating margin - -1128.40%
EBITD margin - -1094.18%
Return on average assets -52.44% -35.95%
Return on average equity -56.16% -39.77%
Employees 102 -
CDP Score - -

Address

441 Charmany Drive
MADISON, WI 53719
United States - Map
+1-608-2845700 (Phone)
+1-608-2845701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company�s Cologuard test is a non-invasive, stool-based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers, which in published studies have been shown to be associated with colorectal cancer. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test (FIT). The Company�s Cologuard test is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. The Company�s Cologuard test includes methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon. By detecting pre-cancers and cancers early with its test, affected patients can be referred to colonoscopy, during which the polyps or lesions can be removed.

Officers and directors

Kevin T. Conroy Chairman of the Board
Age: 48
Bio & Compensation  - Reuters
William J. Megan Principal Financial Officer, Senior Vice President - Finance
Age: 57
Bio & Compensation  - Reuters
Maneesh K. Arora Chief Operating Officer, Senior Vice President
Age: 45
Bio & Compensation  - Reuters
Graham P. Lidgard Ph.D. Senior Vice President, Chief Scientific Officer
Age: 65
Bio & Compensation  - Reuters
David A. Thompson Lead Independent Director
Age: 72
Bio & Compensation  - Reuters
Thomas D. Carey Independent Director
Age: 52
Bio & Compensation  - Reuters
Sally W Crawford Independent Director
Age: 60
Bio & Compensation  - Reuters
Daniel J. Levangie Independent Director
Age: 63
Bio & Compensation  - Reuters
Katherine S. Napier Independent Director
Age: 59
Bio & Compensation  - Reuters